Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Gauthier

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
ACS Applied Materials & Interfaces|December 29, 2011
Drop detachment and motion on fuel cell electrode materialsEric Gauthier, Thomas Hellstern, Ioannis G Kevrekidis, et al.
Coronary Artery Disease|June 22, 2013
Depletion of systemic concentrations of coagulation factors in blood from patients with atherosclerotic vascular diseaseKathleen E Brummel-Ziedins, Phillip H Lam, Matthew Gissel, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 20, 2004
Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantationRenaud Snanoudj, Antoine Durrbach, Eric Gauthier, et al.
Investigational New Drugs|August 11, 2010
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumorsAndrea Wang-Gillam, Susanne M Arnold, Ronald M Bukowski, et al.
Targeted Oncology|October 14, 2025
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast CancerRichard S Finn, Hope S Rugo, Javier Cortes, et al.
Future Oncology (London, England)|October 27, 2025
Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARISDebu Tripathy, Joanne L Blum, Steven McCune, et al.
Targeted Oncology|June 24, 2025
Relationship of Prior Anticancer Treatments with Palbociclib Clinical Outcomes in Patients with HR<sup>+</sup>/HER2<sup>-</sup> Advanced Breast Cancer in Real-World SettingsGabrielle B Rocque, Joanne L Blum, Yan Ji, et al.
The Oncologist|June 21, 2019
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 TrialVéronique Diéras, Nadia Harbeck, Anil Abraham Joy, et al.
The Oncologist|October 30, 2024
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trialDebu Tripathy, Joanne L Blum, Meghan S Karuturi, et al.
Breast Cancer Research and Treatment|November 24, 2024
Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARISGabrielle B Rocque, Joanne L Blum, Yan Ji, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
ACS Applied Materials & Interfaces|December 29, 2011
Drop detachment and motion on fuel cell electrode materialsEric Gauthier, Thomas Hellstern, Ioannis G Kevrekidis, et al.
Coronary Artery Disease|June 22, 2013
Depletion of systemic concentrations of coagulation factors in blood from patients with atherosclerotic vascular diseaseKathleen E Brummel-Ziedins, Phillip H Lam, Matthew Gissel, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 20, 2004
Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantationRenaud Snanoudj, Antoine Durrbach, Eric Gauthier, et al.
Investigational New Drugs|August 11, 2010
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumorsAndrea Wang-Gillam, Susanne M Arnold, Ronald M Bukowski, et al.
Targeted Oncology|October 14, 2025
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast CancerRichard S Finn, Hope S Rugo, Javier Cortes, et al.
Future Oncology (London, England)|October 27, 2025
Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARISDebu Tripathy, Joanne L Blum, Steven McCune, et al.
Targeted Oncology|June 24, 2025
Relationship of Prior Anticancer Treatments with Palbociclib Clinical Outcomes in Patients with HR<sup>+</sup>/HER2<sup>-</sup> Advanced Breast Cancer in Real-World SettingsGabrielle B Rocque, Joanne L Blum, Yan Ji, et al.
The Oncologist|June 21, 2019
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 TrialVéronique Diéras, Nadia Harbeck, Anil Abraham Joy, et al.
The Oncologist|October 30, 2024
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trialDebu Tripathy, Joanne L Blum, Meghan S Karuturi, et al.
Breast Cancer Research and Treatment|November 24, 2024
Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARISGabrielle B Rocque, Joanne L Blum, Yan Ji, et al.
Pageof 3